Member Posts > Hope for Heart Failure Patients: CRD-38 Shows Promise in Landmark Study
For patients suffering from heart failure with preserved ejection fraction (HFpEF), new treatment options are desperately needed. A recent study published in JAC: Basic to Translational Science highlights the potential of CRD-38, a subcutaneous cannabidiol therapy, to improve heart function and reduce disease progression.
Patients could benefit from better cardiac function, lower inflammation, and protection against heart cell damage-a major step forward in HFpEF care.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx